U.S. Markets closed

IsoRay, Inc. (ISR)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.56+0.02 (+3.28%)
At close: 3:59PM EDT

0.58 +0.04 (6.97%)
After hours: 7:47PM EDT

People also watch

IsoRay, Inc.

350 Hills Street
Suite 106
Richland, WA 99354
United States

IndustryMedical Instruments & Supplies
Full Time Employees41

Key Executives

Mr. Thomas C. LaVoy CPAChairman & CEO119.11kN/A57
Mr. William Cavanagh IIIChief Operating Officer and Chief Scientific Officer200.91kN/A51
Mr. Michael L. KrachonVP of Sales and Marketing60.58kN/A46
Mr. Mark Austin CPAPrincipal Accounting & Financial Officer and ControllerN/AN/AN/A
Jennifer StreeterVP of HRN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IsoRay, Inc. develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.

Corporate Governance

IsoRay, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.